Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Human immunoglobulin is a sterile solution made from human plasma. Diseases such as primary immunodeficiency are treated by administering human immunoglobulin through intravenous injection (IGIV). Human immunoglobulin also helps in increasing the platelets (blood clotting cells) in people with immune thrombocytopenic purpura and prevents infections in people with B-cell chronic lymphocytic leukemia. Patients of Kawasaki syndrome are administered human immunoglobulin to prevent aneurysm caused due to weakening of the main artery in the heart.
Furthermore, intravenous human immunoglobulin (pH4) is being extensively researched in order to develop a treatment of COVID-19. This is likely to drive demand of human immunoglobulin (pH4) for intravenous injection and boost the growth of the global human immunoglobulin (ph4) for intravenous injection (COVID-19) market during the forecast period.
The global human immunoglobulin (pH4) for intravenous injection (COVID-19) market is estimated to be valued at US$ 43,205.84 million in 2020 and is expected to exhibit a CAGR of 12.7% during the forecast period (2020-2027).
Figure 1. Global Human Immunoglobulin (ph4) for Intravenous Injection (COVID-19) Market Value (US$ Mn), by Region, 2020
The increasing incidence of disease outbreaks is expected to propel the market growth during the forecast period
The increasing incidence of disease outbreaks is escalating demand for advanced diagnostic measures, which is expected to boost growth of the human immunoglobulin (pH4) for Intravenous Injection (COVID-19) market. For instance, the coronavirus disease (COVID-19) pandemic is the most recent outbreak which was first reported on December 31, 2019 in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the World Health Organization (WHO), around 1,991,562 cases of the coronavirus disease (COVID-19) were reported on April 16, 2020 across the globe.
Figure 2. Global Human Immunoglobulin (ph4) for Intravenous Injection (COVID-19) Market Value Share (%), by Disease Indication, 2020
The increasing approval of intravenous human immunoglobulin products is expected to drive the market growth during the forecast period
Approvals of intravenous human immunoglobulin products by regulatory authorities are expected to drive the growth of the human immunoglobulin (pH4) for intravenous injection (COVID-19) market during the forecast period. For instance, in September 2017, CSL Behring received the U.S. Food and Drug Administration (FDA) approval for Privigen, a human immune globulin intravenous liquid, indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Restraint
Side effects such as headache, cough, fatigue, infusion site reaction, nausea, urticaria, sinusitis, blood pressure increased, diarrhea, dizziness, and lethargy that are associated with human immunoglobulin (pH4) for intravenous injection are expected to hinder the market growth. For instance, on July 2017, Octapharma USA Inc. issued voluntary market withdrawal of one lot of Octagam, a human immune globulin intravenous liquid, as a result of increased hypersensitivity events such as urticaria, wheezing and anaphylactoid-type responses.
Major players operating in the global human immunoglobulin (pH4) for intravenous injection (COVID-19) market are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.